reach study semaglutide Efficacy and safety of once-weekly 2·4 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial Efficacy and tolerability by semaglutide

The protocol was registered in PROSPERO (ID: CRD420251151333)

Semaglutide reduces insulin requirements almost independent of weight loss in the early course of the treatment. In ADJUST-T1D, participants receiving semaglutide started the drug at a once-weekly 0.25 mg dose for 4 weeks, increasing to 0.5 mg at 4 weeks and 1 mg at 8 weeks for the remainder of the trial

Many individuals notice improvements in chronic health markers linked to serious conditions such as heart disease and diabetes

Zepbound (Tirzepatide) Zepbound is a once-weekly injection that targets two hormones, GLP-1 and GIP, for enhanced weight loss results